Profile picture

Doctor Joost van Middendorp

Gent (Netherlands (The))
Follow
Logo ESC

Contributor content

Treatment of Post-COVID-19 POTS by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod
Presentation
Treatment of Post-COVID-19 POTS by inhibiting FcRn: a phase 2 randomized, placebo controlled, double-blind, proof of concept study with efgartigimod
Read more

ESC 365 is supported by

novartis Explore sponsored resources